TXT In plain English
Company description
TEVA UK LIMITED is a UK company whose Companies House status is “Active” and whose registered company type is “Private Limited Company”. Incorporated on 1 July 1935; registered for 91 years; registered office reported in CASTLEFORD, ENGLAND, ENGLAND. Its primary declared activity is 21200 · Manufacture of pharmaceutical preparations.
This BritDB profile also contains linked public records: 2 PSC records, 30 trade marks, 23 procurement records. This description is assembled from public data, is not a reliability assessment, and should be checked against the cited sources before a legally significant decision.
Web facts are never added from a name match alone. Internet enrichment requires the exact Companies House ID in Wikidata, and ambiguous results are excluded.
01 Company overview
Identity and registration
- Official name
- TEVA UK LIMITED
- Company number
- 00302461
- Company type
- Private Limited Company
- Status
- Active
- Country of origin
- United Kingdom
- Dissolution date
- Not supplied
- Accounts category
- FULL
- Mortgage charges
- 8 total · 0 outstanding · 8 satisfied
- Limited partnership members
- 0 general · 0 limited
A registered office is not necessarily a trading location. The address is reproduced from the Companies House bulk record and should be interpreted in that legal context.
02 Filing dates
Accounts and statements
Last accounts made up to
31 December 2024Next accounts due
30 September 2026Last statement made up to
14 January 2026Next statement due
28 January 2027BritDB does not infer overdue status when the source does not state it.
03 Workforce reporting
Gender pay gap
- Median bonus gap
- 39.0%
- Mean bonus gap
- 48.0%
- Women receiving bonus
- 100.0%
- Men receiving bonus
- 100.0%
- Women in top quartile
- 43.0%
- Women in upper middle quartile
- 58.0%
- Women in lower middle quartile
- 63.0%
- Women in lower quartile
- 61.0%
Earlier reporting years (8)
- 250 to 49913.0% median hourly gap
- 250 to 49916.6% median hourly gap
- 250 to 49921.7% median hourly gap
- 250 to 49918.5% median hourly gap
- 500 to 99911.6% median hourly gap
- 500 to 99912.3% median hourly gap
- 500 to 9997.0% median hourly gap
- 500 to 9998.0% median hourly gap
Positive gaps mean men were paid more; negative gaps mean women were paid more. These figures are employer-reported and describe the workforce distribution, not equal pay for the same job. The company link uses the exact Companies House number supplied by the service.
04 Supplier payments
Payment practices and performance
- Reporting period
- 1 January 2026 – 30 June 2026
- Filed
- 30 July 2026
- Shortest standard term
- 120 days
- Longest standard term
- Not supplied
- E-invoicing offered
- No
- Supply-chain finance
- Offered
- Payment codes
- No
- Construction retentions
- No qualifying construction contracts
Complete reported payment fields
- Policy regime
- Regime-3
- Financial period started
- 1 January 2026
- Qualifying contracts
- Yes
- Payments made
- Yes
- Invoice value paid within 30 days
- £666,000
- Invoice value paid in 31–60 days
- £3,349,000
- Invoice value paid after 60 days
- £22,628,000
- Invoice value paid outside agreed terms
- £6,708,000
- Invoices paid in 31–60 days
- 17.0%
- Invoices unpaid due to dispute
- 4.0%
- Maximum contractual payment period
- 120 days
- Supplier-list charging policy
- No
- Supplier-list charges made
- No
Reported terms and dispute process
- Standard payment terms
Standard payment terms are 120 days paid on the 10th or 25th of the month. We do have vendors on payment terms which are different to the standard
- Dispute resolution process
Invoices are sent to the PO requester or approver for review via ERP system and discrepancies are raised with the vendor. Queries may also be communicated to the Finance Shared Services team, who would return the invoice and advise vendor of the query and reason for non-payment for resolution
Earlier payment reports (11 shown)
- 79.0 average days to pay20.0% outside terms
- 82.0 average days to pay19.0% outside terms
- 72.0 average days to pay20.0% outside terms
- 72.0 average days to pay33.0% outside terms
- 68.0 average days to pay30.0% outside terms
- 52.0 average days to pay21.0% outside terms
- 82.0 average days to pay18.0% outside terms
- 67.0 average days to pay19.0% outside terms
- 71.0 average days to pay14.0% outside terms
- 68.0 average days to pay20.0% outside terms
- 58.0 average days to pay14.0% outside terms
This is a company-submitted statutory disclosure, not a credit rating. BritDB preserves the reporting period and links the report only through the Companies House number supplied by the official service. Percentages describe payments made during that period and may change in later reports.
05 Supply-chain transparency
Modern slavery statement
- Organisation
- TEVA UK LIMITED
- Group submission
- Yes
- Statement period
- 1 January 2025 – 31 December 2025
- Approved
- 17 June 2026
- Sectors
- Healthcare and pharmaceuticals
Organisation structure
Covered in the statement
Policies
Covered in the statement
Risk assessment
Covered in the statement
Due diligence
Covered in the statement
Training
Covered in the statement
Goals and KPIs
Not reported as covered
Full statement information supplied to the registry
- Reported turnover band
- £100 million to £500 million
- Years producing statements
- 1 to 5 years
- ILO indicators included
- Not answered
- Registry record updated
- 1 July 2026
A registry entry records what the organisation declared in its statement. It is not an independent audit. Group statements can cover several companies; BritDB preserves each exact source-supplied company-number link and excludes approver names and email addresses.
06 Data protection
ICO fee-payer registration
Teva UK Limited
Registration Z1948892
- Registered from
- 9 October 2009
- Current end date
- 8 October 2027
This is a candidate association, not an official Companies House link. The ICO file supplies no company number. The organisation name and postcode uniquely matched this company in the current snapshot. BritDB excludes all DPO contact fields and does not publish unmatched personal entries.
07 Public procurement
Contracts Finder awards
National Microbiology Framework - Lot 2: Research and Development Goods and Services
Public Health England · ocds-b5fd17-14133027-6a6f-4a1f-8518-268021f54a78
- Supplier named in award
- Teva UK Ltd
- Award value
- £1,500,000,000
- Contract period
- 23 April 2021 – 22 April 2023
- Published
- 10 May 2021
- Procedure
- Open procedure (above threshold)
- Main CPV
- 33000000
- Source release ID
- ocds-b5fd17-14133027-6a6f-4a1f-8518-268021f54a78-2021-05-10T17:53:56+01:00
National Microbiology Framework - Lot 2: Research and Development Goods and Services
Public Health England · ocds-b5fd17-14133027-6a6f-4a1f-8518-268021f54a78
- Supplier named in award
- Teva UK Ltd
- Award value
- £1,500,000,000
- Contract period
- 23 April 2021 – 22 April 2023
- Published
- 10 May 2021
- Procedure
- Open procedure (above threshold)
- Main CPV
- 33000000
- Source release ID
- ocds-b5fd17-14133027-6a6f-4a1f-8518-268021f54a78-2021-05-10T17:53:56+01:00
National Microbiology Framework - Lot 1: Diagnostic Goods and Services
Public Health England · ocds-b5fd17-f7d14908-7da1-4faa-8801-324f837a758e
- Supplier named in award
- Teva UK Ltd
- Award value
- £3,000,000,000
- Contract period
- 9 April 2021 – 8 April 2023
- Published
- 19 April 2021
- Procedure
- Open procedure (above threshold)
- Main CPV
- 33000000
- Source release ID
- ocds-b5fd17-f7d14908-7da1-4faa-8801-324f837a758e-2021-04-19T13:15:19+01:00
NHS Framework, North of England, Branded Medicines-Tranche A and Annual Tranche
NHS England · ocds-b5fd17-711f74f7-430c-4b80-a5e0-b3ce69f928b9
- Supplier named in award
- Teva UK Limited
- Award value
- £1
- Contract period
- 1 March 2021 – 28 February 2023
- Published
- 13 May 2021
- Procedure
- Open procedure (above threshold)
- Main CPV
- 33600000
- Source release ID
- ocds-b5fd17-711f74f7-430c-4b80-a5e0-b3ce69f928b9-2021-05-13T10:21:38+01:00
NHS Framework for the Midlands and East, Branded Medicines - Tranche B
NHS England · ocds-b5fd17-a3813112-7a5b-461b-9e42-ccdb117c93ef
- Supplier named in award
- Teva UK Limited
- Award value
- £228,156,862
- Contract period
- 1 March 2021 – 28 February 2023
- Published
- 30 April 2021
- Procedure
- Open procedure (above threshold)
- Main CPV
- 33600000
- Source release ID
- ocds-b5fd17-a3813112-7a5b-461b-9e42-ccdb117c93ef-2021-04-30T13:00:26+01:00
NHS Framework for the NHS London Region, Branded Medicines - Tranche A
NHS England · ocds-b5fd17-20ae12c6-3ba8-40bb-b423-51a2c2de6a67
- Supplier named in award
- Teva UK Limited
- Award value
- £191,062,951
- Contract period
- 1 September 2020 – 31 August 2022
- Published
- 15 September 2020
- Procedure
- Open procedure (above threshold)
- Main CPV
- 33600000
- Source release ID
- ocds-b5fd17-20ae12c6-3ba8-40bb-b423-51a2c2de6a67-2020-09-15T14:26:04+01:00
Contracts for the supply of Azithromycin & Dexamethasone products pt2
Department of Health and Social Care · ocds-b5fd17-15e59374-9657-49f6-9967-394f00bbe769
- Supplier named in award
- Teva UK Ltd
- Award value
- £2,108,686.32
- Contract period
- 11 May 2020 – 31 May 2020
- Published
- 18 June 2020
- Procedure
- Negotiated procedure without prior publication (above threshold)
- Main CPV
- 33600000
- Source release ID
- ocds-b5fd17-15e59374-9657-49f6-9967-394f00bbe769-2020-06-18T15:14:53+01:00
Contracts for the supply of Azithromycin & Dexamethasone products pt1
Department of Health and Social Care · ocds-b5fd17-3d6de0dd-0aaa-4680-89f6-c36e64ccadcd
- Supplier named in award
- Teva UK Ltd
- Award value
- £305,793.80
- Contract period
- 23 April 2020 – 31 May 2020
- Published
- 17 June 2020
- Procedure
- Negotiated procedure without prior publication (above threshold)
- Main CPV
- 33600000
- Source release ID
- ocds-b5fd17-3d6de0dd-0aaa-4680-89f6-c36e64ccadcd-2020-06-17T11:18:09+01:00
NHS Framework Agreement - North of England - Tranche B
NHS England · ocds-b5fd17-2774d91d-05e7-400d-a217-4a5ca9db01ef
- Supplier named in award
- TEVA UK LIMITED
- Award value
- £205,535,556
- Contract period
- 1 March 2020 – 28 February 2022
- Published
- 25 March 2020
- Procedure
- Open procedure (above threshold)
- Main CPV
- 33600000
- Source release ID
- ocds-b5fd17-2774d91d-05e7-400d-a217-4a5ca9db01ef-2020-03-25T08:39:13Z
NHS Midlands and East Branded Medicines - Tranche A
NHS England · ocds-b5fd17-1d021051-40c8-4883-ba04-47625826b7b8
- Supplier named in award
- TEVA UK Ltd
- Award value
- £418,787,000
- Contract period
- 1 March 2020 – 28 February 2022
- Published
- 13 February 2020
- Procedure
- Open procedure (above threshold)
- Main CPV
- 33600000
- Source release ID
- ocds-b5fd17-1d021051-40c8-4883-ba04-47625826b7b8-2020-02-13T09:40:57Z
NHS Framework Agreement for Branded Medicines - National
NHS England · ocds-b5fd17-67d93048-4af9-4a0e-b313-bc852f01fca7
- Supplier named in award
- TEVA UK LIMITED
- Award value
- £1,351,341,890
- Contract period
- 1 May 2019 – 30 April 2021
- Published
- 9 August 2019
- Procedure
- Open procedure (above threshold)
- Main CPV
- 33600000
- Source release ID
- ocds-b5fd17-67d93048-4af9-4a0e-b313-bc852f01fca7-2019-08-09T15:57:38+01:00
NHS England - Midlands and East Branded Medicines - Tranche B
NHS England · ocds-b5fd17-6c7a4e2c-58d3-4c41-8f77-dc419f83871c
- Supplier named in award
- Teva UK Limited
- Award value
- £295,035,882
- Contract period
- 1 March 2019 – 28 March 2021
- Published
- 9 April 2019
- Procedure
- Open procedure (above threshold)
- Main CPV
- 33600000
- Source release ID
- ocds-b5fd17-6c7a4e2c-58d3-4c41-8f77-dc419f83871c-2019-04-09T11:25:43+01:00
NHS England - Midlands and East Branded Medicines - Tranche B
NHS England · ocds-b5fd17-9878d09a-d11a-4940-a851-2b2b759217f2
- Supplier named in award
- Teva UK Limited
- Award value
- £295,035,882
- Contract period
- 1 March 2019 – 28 March 2021
- Published
- 9 April 2019
- Procedure
- Open procedure (above threshold)
- Main CPV
- 33600000
- Source release ID
- ocds-b5fd17-9878d09a-d11a-4940-a851-2b2b759217f2-2019-04-09T11:04:50+01:00
NHS England - Midlands and East Branded Medicines - Tranche B
NHS England · ocds-b5fd17-679e36df-b147-44d9-b0c1-53e4b91250c8
- Supplier named in award
- Teva UK Limited
- Award value
- £295,035,882
- Contract period
- 1 March 2019 – 28 March 2021
- Published
- 9 April 2019
- Procedure
- Open procedure (above threshold)
- Main CPV
- 33600000
- Source release ID
- ocds-b5fd17-679e36df-b147-44d9-b0c1-53e4b91250c8-2019-04-09T10:58:14+01:00
NHS England - Midlands and East Branded Medicines - Tranche B
NHS England · ocds-b5fd17-8aaddf75-dd22-4754-b241-885b44819814
- Supplier named in award
- Teva UK Limited
- Award value
- £295,035,882
- Contract period
- 1 March 2019 – 28 March 2021
- Published
- 21 March 2019
- Procedure
- Open procedure (above threshold)
- Main CPV
- 33600000
- Source release ID
- ocds-b5fd17-8aaddf75-dd22-4754-b241-885b44819814-2019-03-21T11:50:47Z
The supplier link is exact, but the award remains buyer-published procurement data. BritDB requires the GB-COH identifier supplied in the Contracts Finder OCDS release and does not infer suppliers from similar names.
TM UK trade marks
Exact owner-name matches
TYMBRINEB
Owner Teva UK Limited · classes 5
- Filed / designated
- 22 May 2017
- Valid until / renewal due
- 22 May 2027
GAZYLAN
Owner TEVA UK Limited · classes 5
- Filed / designated
- 9 September 2015
- Valid until / renewal due
- 9 September 2025
MARIOSEA
Owner Teva UK Limited · classes 5
- Filed / designated
- 13 November 2014
- Valid until / renewal due
- 13 November 2024
STANEK
Owner TEVA UK Limited · classes 5
- Filed / designated
- 2 April 2014
- Valid until / renewal due
- 2 April 2024
MAFAMOZ
Owner TEVA UK Limited · classes 5
- Filed / designated
- 21 August 2013
- Valid until / renewal due
- 21 August 2023
DALBECAL
Owner TEVA UK Limited · classes 5
- Filed / designated
- 21 August 2013
- Valid until / renewal due
- 21 August 2023
EVACAL D3
Owner TEVA UK Limited · classes 5
- Filed / designated
- 17 January 2013
- Valid until / renewal due
- 17 January 2023
MACILAX
Owner TEVA UK Limited · classes 5
- Filed / designated
- 1 March 2011
- Valid until / renewal due
- 1 March 2021
MACILAX PAEDIATRIC
Owner TEVA UK Limited · classes 5
- Filed / designated
- 1 March 2011
- Valid until / renewal due
- 1 March 2021
TEVAONE
Owner TEVA UK Limited · classes 5
- Filed / designated
- 6 January 2011
- Valid until / renewal due
- 6 January 2021
TEVATWO
Owner TEVA UK Limited · classes 5
- Filed / designated
- 6 January 2011
- Valid until / renewal due
- 6 January 2021
MUR ADVANTAGE
Owner TEVA UK Limited · classes 44
- Filed / designated
- 27 September 2010
- Valid until / renewal due
- 27 September 2020
VERTINE
Owner TEVA UK Limited · classes 5
- Filed / designated
- 25 June 2010
- Valid until / renewal due
- 25 June 2020
PriceWatch PREVIEW
Owner Teva UK Limited · classes 35
- Filed / designated
- 28 May 2010
- Valid until / renewal due
- 28 May 2020
PriceWatch PREVIEW
Owner Teva UK Limited · classes 35
- Filed / designated
- 27 May 2010
- Valid until / renewal due
- 27 May 2020
SPOTLIGHT
Owner TEVA UK Limited · classes 5,44
- Filed / designated
- 22 April 2010
- Valid until / renewal due
- 22 April 2020
CPXtra Level Two
Owner Teva UK Limited · classes 35,36
- Filed / designated
- 6 April 2010
- Valid until / renewal due
- 6 April 2020
CPXtra
Owner Teva UK Limited · classes 35,36
- Filed / designated
- 6 April 2010
- Valid until / renewal due
- 6 April 2020
Figurative mark
Owner Teva UK Limited · classes 35
- Filed / designated
- 6 April 2010
- Valid until / renewal due
- 6 April 2020
PriceWatch
Owner Teva UK Limited · classes 35
- Filed / designated
- 6 April 2010
- Valid until / renewal due
- 6 April 2020
ultimate
Owner Teva UK Limited · classes 35,36
- Filed / designated
- 6 April 2010
- Valid until / renewal due
- 6 April 2020
ultimate PARTNERS
Owner Teva UK Limited · classes 35,36
- Filed / designated
- 6 April 2010
- Valid until / renewal due
- 6 April 2020
CPXtra Level One
Owner Teva UK Limited · classes 35,36
- Filed / designated
- 6 April 2010
- Valid until / renewal due
- 6 April 2020
THE NATION'S MEDICINE CABINET
Owner Teva UK Limited · classes 5,44
- Filed / designated
- 23 December 2008
- Valid until / renewal due
- 23 December 2018
Marol
Owner Teva UK Limited · classes 5
- Filed / designated
- 25 July 2008
- Valid until / renewal due
- 25 July 2018
MARCH Management and Awareness of Risks of Cytotoxic Handling
Owner Teva UK Limited · classes 5
- Filed / designated
- 15 May 2007
- Valid until / renewal due
- 15 May 2027
MARCH Management and Awareness of Risks of Cytotoxic Handling
Owner Teva UK Limited · classes 5
- Filed / designated
- 15 May 2007
- Valid until / renewal due
- 15 May 2027
MARCH
Owner Teva UK Limited · classes 5
- Filed / designated
- 15 May 2007
- Valid until / renewal due
- 15 May 2027
MARCH
Owner Teva UK Limited · classes 5
- Filed / designated
- 15 May 2007
- Valid until / renewal due
- 15 May 2027
EPITOIN
Owner Teva UK Limited · classes 5
- Filed / designated
- 11 April 2007
- Valid until / renewal due
- 11 April 2027
This is an exact normalised company-name match, not a registrar-confirmed ownership link. Another legal entity can have the same or a very similar name. UKIPO data is a historical 2018 snapshot; verify the owner and current status before relying on it.
08 Ownership and control
People with significant control
Teva Pharma Holdings Limited
- Owns 75% or more of shares
- Controls 75% or more of voting rights
- Can appoint or remove directors
- Country registered
- England And Wales
- Legal authority
- United Kingdom (England And Wales)
- Legal form
- Limited By Shares
- Place registered
- Companies House
- Registration number
- 10119709
- Notified
- 5 November 2024
Teva Uk Holdings Limited
- Owns 75% or more of shares
- Controls 75% or more of voting rights
- Can appoint or remove directors
- Country registered
- United Kingdom
- Legal authority
- Companies Act
- Legal form
- Private Company
- Place registered
- Companies House, England & Wales
- Registration number
- 04539805
- Notified
- 6 April 2016
- Ceased
- 5 November 2024
PSC records are company-filed public-register information. When the exact same displayed individual name occurs at multiple companies, BritDB offers a non-indexed cross-reference page. It is a name match only, not proof that the records describe the same person. Service addresses and partial dates of birth are deliberately omitted.
09 Charity register
Charity Commission links
No exact company-number link in this snapshot
The Charity Commission extract did not explicitly associate this Companies House number with a charity. BritDB does not use a name-only match to fill the gap.
This company-level check covers the Charity Commission for England and Wales. Links are accepted only when the official extract supplies this exact company registration number. Scottish charities now have separate OSCR profiles, but OSCR’s bulk fields do not provide a Companies House number, so BritDB does not infer a company link.
10 Northern Ireland charity register
CCNI exact company links
No unambiguous company-number link found
The CCNI source number did not resolve uniquely to this Companies House record. BritDB did not use a name or address match.
CCNI publishes company numbers without a jurisdiction prefix. BritDB links only when the plausible padded UK and NI candidates resolve to exactly one Companies House company.
11 Sanctions screening
UK Sanctions List
No exact business-registration-number link found
The imported UK Sanctions List did not supply this Companies House number as a UK-linked business identifier. BritDB did not attempt a name-only match.
No exact link is not sanctions clearance. UK restrictions can apply through ownership or control even where an entity is not separately named. Always use the current official list and obtain appropriate advice for a legally significant decision.
12 Public procurement
Find a Tender links
Generic, Branded Generic & Proprietary Medicinal Products - Group 18
Regional Business Services Organisation, Procurement and Logistics Service · updated 3 July 2026
- Tender value
- £1,800,000,000
- Awards
- 214
NHS National Transition Framework for Apremilast, Pazopanib and Dapagliflozin
NHS England · updated 30 January 2026
- Tender value
- £37,954,000
- Awards
- 2
NHS National Framework for Generics Housekeeping
NHS England · updated 22 December 2025
- Tender value
- £52,023,284
- Awards
- 2
NHS National Framework for Denosumab Injection commencing 1st January 2026
NHS England · updated 4 December 2025
- Tender value
- £57,000,000
- Awards
- 2
NHS National Framework for Medical Retinal Vascular Treatments - 1 December 2025
NHS England · updated 6 October 2025
- Tender value
- £1,520,432,295
- Awards
- 3
NHS National Framework for Transition products (Axitinib and Eltrombopag)
NHS England · updated 4 September 2025
- Tender value
- £80,909,200
- Awards
- 1
NHS National Framework for Transition Products (Nintedanib and Dalbavancin)
NHS England · updated 24 April 2026
- Tender value
- £115,756,000
- Awards
- 2
NHS National Framework for Transition products (Nilotinib and Ticagrelor)
NHS England · updated 20 August 2025
- Tender value
- £29,042,000
- Awards
- 2
These links use only the GB-COH identifier supplied in the procurement record. A company may have other public-sector work that is absent, older, below publication thresholds or published without a Companies House identifier.
13 Environmental register
Environment Agency waste registrations
No exact company-number registration linked
The licensed Environment Agency subset did not contain this exact Companies House number. BritDB did not attempt a name-only match.
This is a privacy-reduced, exact-company subset. The full official register also includes sole traders and applicants without a matching Companies House number. Check the current Environment Agency register before relying on registration status.
14 Nature of business
Standard Industrial Classification
15 Connected public record
Checks beyond the company register
Charity Commission
0 exact company-number links.
Northern Ireland charities
0 unambiguous company-number links.
Public contracts
8 procurement processes linked by exact GB-COH identifier.
Waste register
0 exact company-number registrations.
Corporate notices
The Gazette is not yet connected.
UK Sanctions List
No exact business-registration-number link in this report.
A checked source with no exact link is not a clean bill of health. Unchecked sources remain unknown, while sanctions may also apply through ownership or control of a listed person or entity.
16 Record timeline
Dates in the bulk record
- Confirmation statement
Latest confirmation statement made up to this date
- Accounts
Latest accounts made up to this date
- Incorporation
Company incorporated
17 Provenance
Sources for this profile
Identity, address, status, dates, SIC, previous names and mortgage totals.
Annual employer reports linked by the exact source-supplied Companies House number.
Statutory supplier-payment reports linked by the exact source-supplied Companies House number.
Annual statement summaries linked by exact source company number.
Privacy-reduced candidate associations based on a unique exact name-and-postcode match.
Historic awards linked by exact source-supplied GB-COH company identifier.
Current and ceased significant-control records joined by exact company number.
Daily England and Wales extract matched only by the official company registration number.
Daily CCNI export with company links only where the source number resolves unambiguously.
Complete FCDO list checked by exact UK-linked business registration number.
Procurement parties checked only through exact GB-COH identifiers.
Licensed subset linked only by exact Companies House number.
Financial regulation and licences.
Companies House, Charity Commission, OSCR and UK Sanctions List information is public-register data. BritDB reproduces and organises it with source-specific limits; official external links are kept on the dedicated source pages.